Scinai Immunotherapeutics (SCNI) Common Equity (2015 - 2026)

Scinai Immunotherapeutics has disclosed Common Equity across 12 years of filings, most recently posting $11.7 million for Q2 2026.

• In Q2 2026, Common Equity rose 49.3% year-over-year to $11.7 million; the TTM figure through Jun 2026 stood at $11.7 million (up 49.3% YoY), while the FY2025 annual figure was $8.1 million, down 18.78% from the prior year.
• Common Equity came in at $11.7 million for Q2 2026 at Scinai Immunotherapeutics, roughly flat from $11.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.8 million in Q1 2026 to a low of -$7.3 million in Q2 2024.
• Average Common Equity over 5 years is $1.9 million, with a median of $889500.0 recorded in 2022.
• Year-over-year, Common Equity sank 458.0% in 2023 and surged 471.58% in 2024.
• Over 5 years, Common Equity stood at -$1.8 million in 2022, then plunged by 159.6% to -$4.6 million in 2023, then soared by 318.36% to $10.0 million in 2024, then fell by 18.78% to $8.1 million in 2025, then surged by 44.79% to $11.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $11.7 million in Q2 2026, $11.8 million in Q1 2026, and $8.1 million in Q4 2025.